Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2014 Mar 7

PMID 24599757

Citations 26

Authors

Afef Slimani

Yahia Harira

Imen Trabelsi

Walid Jomaa

Faouzi Maatouk

Khaldoun Ben Hamda

Mohamed Naceur Slimane

Affiliations

Soon will be listed here.

Abstract

The association of E670G (rs505151) polymorphism in PCSK9 gene with an increased risk of coronary artery disease (CAD) and ischemic stroke (IS) was reported in previous studies. We investigated the effect of the E670G (rs505151) on the risk of CAD and IS in a Tunisian cohort. Genotyping of the PCSK9 E670G was performed using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) and then confirmed by direct sequencing. The frequency of the 670G allele was significantly higher in the CAD than in the no-CAD subgroup (0.132 vs. 0.068, p = 0.030). As expected, the incidence of E670G was significantly important in IS subgroup than control group (0.122 vs. 0.073, p = 0.032). Furthermore in CAD patients, the 670G carriers showed significantly increased plasma total cholesterol and LDL-cholesterol levels compared to E670 carriers (6.78 [6.47-7.00] vs. 4.92 [4.02-5.46] mmol/l, p < 0.0001 and 4.60 [4.00-5.04] vs. 3.00 [2.22-3.70] mmol/l p = 0.001, respectively). The risk and severity of CAD were significantly increased in 670G carriers between no-CAD subgroup and CAD patients presenting a stenosis ≥50 % in two or three major coronary arteries (0.068 vs. 0.198, p = 0.001, OR = 3.39 [1.55-7.37]). The E670G polymorphism of the PCSK9 gene is mainly associated with a increased risk and severity of CAD and IS in Tunisian cohort.

Citing Articles

The role of PCSK9 in heart failure and other cardiovascular diseases-mechanisms of action beyond its effect on LDL cholesterol.

Dutka M, Zimmer K, Cwiertnia M, Ilczak T, Bobinski R Heart Fail Rev. 2024; 29(5):917-937.

PMID: 38886277 PMC: 11306431. DOI: 10.1007/s10741-024-10409-7.

E670G PCSK9 polymorphism in HeFH & CAD with diabetes: is the bridge to personalized therapy within reach?.

Alieva R, Shek A, Abdullaev A, Fozilov K, Khoshimov S, Abdullaeva G Front Clin Diabetes Healthc. 2023; 4:1277288.

PMID: 38028979 PMC: 10646404. DOI: 10.3389/fcdhc.2023.1277288.

Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men.

Kunimura A, Miura K, Segawa H, Torii S, Kondo K, Hisamatsu T J Atheroscler Thromb. 2022; 30(7):767-777.

PMID: 36123046 PMC: 10322734. DOI: 10.5551/jat.63549.

Preliminary genome wide screening identifies new variants associated with coronary artery disease in Indian population.

Bhat K, Guleria V, Kumar J R, Rastogi G, Sharma V, Sharma A Am J Transl Res. 2022; 14(7):5124-5131.

PMID: 35958505 PMC: 9360888.

Association of PCSK9 levels and genetic polymorphisms with stroke recurrence and functional outcome after acute ischemic stroke.

Chen W, Wang Y, Meng X, Pan Y, Wang M, Li H Ann Transl Med. 2022; 10(13):729.

PMID: 35957726 PMC: 9358512. DOI: 10.21037/atm-22-870.

References

Cohen J, Pertsemlidis A, Kotowski I, Graham R, Garcia C, Hobbs H . Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37(2):161-5. DOI: 10.1038/ng1509. View

Abifadel M, Rabes J, Boileau C, Varret M . [After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9]. Ann Endocrinol (Paris). 2007; 68(2-3):138-46. DOI: 10.1016/j.ando.2007.02.002. View

Abifadel M, Varret M, Rabes J, Allard D, Ouguerram K, Devillers M . Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34(2):154-6. DOI: 10.1038/ng1161. View

Chan D, Watts G . Postprandial lipoprotein metabolism in familial hypercholesterolemia: thinking outside the box. Metabolism. 2011; 61(1):3-11. DOI: 10.1016/j.metabol.2011.07.014. View

Mbikay M, Sirois F, Mayne J, Wang G, Chen A, Dewpura T . PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2009; 584(4):701-6. DOI: 10.1016/j.febslet.2009.12.018. View

Chen S, Ballantyne C, Gotto Jr A, Tan Y, Willerson J, Marian A . A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005; 45(10):1611-9. PMC: 2910256. DOI: 10.1016/j.jacc.2005.01.051. View

Costet P, Cariou B, Lambert G, Lalanne F, Lardeux B, Jarnoux A . Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem. 2006; 281(10):6211-8. DOI: 10.1074/jbc.M508582200. View

Huang C, Fornage M, Lloyd-Jones D, Wei G, Boerwinkle E, Liu K . Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet. 2009; 2(4):354-61. PMC: 2810147. DOI: 10.1161/CIRCGENETICS.108.828467. View

Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

10.

Zhang D, Lagace T, Garuti R, Zhao Z, McDonald M, Horton J . Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007; 282(25):18602-18612. DOI: 10.1074/jbc.M702027200. View

11.

Hsu L, Teng M, Ko Y, Chang C, Wu S, Wang C . The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan. Clin Chem Lab Med. 2009; 47(2):154-8. DOI: 10.1515/CCLM.2009.032. View

12.

Norata G, Garlaschelli K, Grigore L, Raselli S, Tramontana S, Meneghetti F . Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Atherosclerosis. 2009; 208(1):177-82. DOI: 10.1016/j.atherosclerosis.2009.06.023. View

13.

Sun X, Eden E, Tosi I, Neuwirth C, Wile D, Naoumova R . Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005; 14(9):1161-9. DOI: 10.1093/hmg/ddi128. View

14.

Gotto Jr A, Moon J . Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol. 2012; 110(1 Suppl):3A-14A. DOI: 10.1016/j.amjcard.2012.04.002. View

15.

Lambert G, Jarnoux A, Pineau T, Pape O, Chetiveaux M, Laboisse C . Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. 2006; 147(10):4985-95. DOI: 10.1210/en.2006-0098. View

16.

Rousselet E, Marcinkiewicz J, Kriz J, Zhou A, Hatten M, Prat A . PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. J Lipid Res. 2011; 52(7):1383-91. PMC: 3111744. DOI: 10.1194/jlr.M014118. View

17.

Abdel-Maksoud M, Eckel R, Hamman R, Hokanson J . Risk of coronary heart disease is associated with triglycerides and high-density lipoprotein cholesterol in women and non-high-density lipoprotein cholesterol in men. J Clin Lipidol. 2012; 6(4):374-81. DOI: 10.1016/j.jacl.2012.02.011. View

18.

Stephens M, Sloan J, Robertson P, Scheet P, Nickerson D . Automating sequence-based detection and genotyping of SNPs from diploid samples. Nat Genet. 2006; 38(3):375-81. DOI: 10.1038/ng1746. View

19.

Lagace T, Curtis D, Garuti R, McNutt M, Park S, Prather H . Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006; 116(11):2995-3005. PMC: 1626117. DOI: 10.1172/JCI29383. View

20.

Cunningham D, Danley D, Geoghegan K, Griffor M, Hawkins J, Subashi T . Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007; 14(5):413-9. DOI: 10.1038/nsmb1235. View